Inclusion Criteria:

          1. Documented histological or cytological diagnosis of renal cell carcinoma with a
             clear-cell component

          2. Adult patients

          3. Karnofsky Performance Score (KPS) ≥ 70%

          4. Measurable Disease per RECIST 1.1

          5. 1-2 lines of prior therapy for advanced or metastatic RCC including one
             anti-angiogenic therapy (any VEGF pathway-targeted agent used either as monotherapy or
             as a component of a combination regimen) OR the combination regimen of nivolumab +
             ipilimumab

          6. Adequate hepatic, renal, cardiac and hematologic function

        Exclusion Criteria:

          1. Prior treatment with cabozantinib (or other MET inhibitor) or CB-839

          2. Receipt of other anticancer therapy within 2-6 weeks, depending on the treatment

          3. Untreated or active brain metastases or central nervous system cancer, as defined per
             protocol

          4. Prior gastric surgery, small bowel resection, or other conditions that may impede
             adequate absorption of oral study drug

          5. Known active infection with HIV, Hepatitis B or C virus

          6. Inability to discontinue proton-pump-inhibitor use before randomization

          7. Patients who are pregnant or lactating